DelveInsight’s, “Systemic Sclerosis Pipeline Insight 2023” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in the Systemic Sclerosis pipeline landscape. It covers the Systemic Sclerosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Systemic Sclerosis Pipeline Report

• DelveInsight’s Systemic Sclerosis pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for Systemic Sclerosis treatment.
• The leading companies working in the Systemic Sclerosis Market include Eicos Sciences, Beijing Continent Pharmaceutical, Kyowa Kirin, Cytori therapeutics, Corbus Pharmaceuticals, Zenyaku Kogyo, Sanofi, Bayer, ASKA Pharmaceutical, Emerald Health Pharmaceuticals, United Therapeutics, Cumberland Pharmaceuticals, ILTOO Pharma, Horizon Pharmaceuticals, Janssen Biotech, Gesynta Pharma, Certa Therapeutics, Pfizer, Vicore Pharma, Seagen, CSL Behring, arGentis Pharmaceuticals, Mitsubishi Tanabe Pharma, Kadmon Pharmaceuticals, GlaxoSmithKline, Bristol-Myers Squibb, Camurus, Pfizer, Regeneron Pharmaceuticals, Castle Creek Biosciences, Talaris Therapeutics, Viela Bio, Formation Biologics, Horizon Therapeutics, Chemomab therapeutics, AnaMar, Atlantic Healthcare, D&D Pharmatech, Acceleron Pharma, Riptide Bioscience, Timber Pharmaceuticals, Tvardi Therapeutics, Accuitis Pharmaceuticals, AKL Research and Development, iBio, Blade Therapeutics, Cantargia, BriaCell Therapeutics, Leadiant Biosciences, and others.
• Promising Systemic Sclerosis Pipeline Therapies in the various stages of development include GS-248, KHK4827, Paquinimod, Inebilizumab, Nemolizumab, RO7303509, Treprostinil Diethanolamine, and others.
• September 2023: Horizon Pharma Ltd announced a study of phase 2 clinical trials for HZN-825 BID. All participants who complete the Double-blind Treatment Period (Week 52) will be eligible to enter a 52-week extension trial (HZNP-HZN-825-302, NCT05626751). Participants not entering the extension trial will participate in a Safety Follow-up Visit 4 weeks after the last dose of trial drug.
• September 2023: Hospital for Special Surgery, New York announced a study of phase 2 clinical trials for Belimumab, and MMF. After patients maintain a stable dose of Mycophenolate Mofetil (MMF) for at least 1 month, they will be randomized to treatment with either Belimumab & Rituximab or placebo. Patients in both groups will be on background MMF for the entirety of the study. Belimumab will be administered subcutaneously and Rituximab intravenously.

 

Request a sample and discover the recent advances in Systemic Sclerosis Treatment Drugs @ Systemic Sclerosis Pipeline Report

 

In the Systemic Sclerosis pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Systemic Sclerosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Systemic Sclerosis Overview

Scleroderma, also known as Systemic Sclerosis, progressive systemic sclerosis or the CREST syndrome, is a chronic skin disorder that affects the skin, connective tissues and other internal organs. The disorder takes place sin humans, when the immune system causes the body to make the protein collagen, an important component of the skin, in huge amounts.

 

Find out more about Systemic Sclerosis Therapeutics Assessment @ Systemic Sclerosis Preclinical and Discovery Stage Products

 

Systemic Sclerosis Emerging Drugs Profile

• Iloprost: Eicos Sciences
• ECCS 50: Cytori therapeutics
• Lenabasum (JBT-101): Corbus Pharmaceuticals
• EHP-101: Emerald Health Pharmaceuticals

 

Systemic Sclerosis Pipeline Therapeutics Assessment

There are approx. 50+ key companies which are developing the Systemic Sclerosis therapies. The Systemic Sclerosis companies which have their Systemic Sclerosis drug candidates in the most advanced stage, i.e. Phase III include, Eicos Sciences.

 

Learn more about the emerging Systemic Sclerosis Pipeline Therapies @ Systemic Sclerosis Clinical Trials Assessment

 

Scope of the Systemic Sclerosis Pipeline Report

• Coverage- Global
• Systemic Sclerosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Systemic Sclerosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Systemic Sclerosis Companies- Eicos Sciences, Beijing Continent Pharmaceutical, Kyowa Kirin, Cytori therapeutics, Corbus Pharmaceuticals, Zenyaku Kogyo, Sanofi, Bayer, ASKA Pharmaceutical, Emerald Health Pharmaceuticals, United Therapeutics, Cumberland Pharmaceuticals, ILTOO Pharma, Horizon Pharmaceuticals, Janssen Biotech, Gesynta Pharma, Certa Therapeutics, Pfizer, Vicore Pharma, Seagen, CSL Behring, arGentis Pharmaceuticals, Mitsubishi Tanabe Pharma, Kadmon Pharmaceuticals, GlaxoSmithKline, Bristol-Myers Squibb, Camurus, Pfizer, Regeneron Pharmaceuticals, Castle Creek Biosciences, Talaris Therapeutics, Viela Bio, Formation Biologics, Horizon Therapeutics, Chemomab therapeutics, AnaMar, Atlantic Healthcare, D&D Pharmatech, Acceleron Pharma, Riptide Bioscience, Timber Pharmaceuticals, Tvardi Therapeutics, Accuitis Pharmaceuticals, AKL Research and Development, iBio, Blade Therapeutics, Cantargia, BriaCell Therapeutics, Leadiant Biosciences, and others.
• Systemic Sclerosis Pipeline Therapies- GS-248, KHK4827, Paquinimod, Inebilizumab, Nemolizumab, RO7303509, Treprostinil Diethanolamine, and others.

 

Dive deep into rich insights for new drugs for Systemic Sclerosis Treatment, Visit @ Systemic Sclerosis Market Drivers and Barriers, and Future Perspective

 

Table of Content

1. Introduction
2. Executive Summary
3. Systemic Sclerosis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Late Stage Products (Phase III)
7. Iloprost: Eicos Sciences
8. Drug profiles in the detailed report…..
9. Mid Stage Products (Phase II)
10. EHP-101: Emerald Health Pharmaceuticals
11. Drug profiles in the detailed report…..
12. Early stage products (Phase I)
13. VIB7734: Viela Bio
14. Drug profiles in the detailed report…..
15. Inactive Products
16. Systemic Sclerosis Key Companies
17. Systemic Sclerosis Key Products
18. Systemic Sclerosis- Unmet Needs
19. Systemic Sclerosis- Market Drivers and Barriers
20. Systemic Sclerosis- Future Perspectives and Conclusion
21. Systemic Sclerosis Analyst Views
22. Systemic Sclerosis Key Companies
23. Appendix

 

For further information on the Systemic Sclerosis pipeline therapeutics, reach out to Systemic Sclerosis Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/ci-tracking